Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 6CNS 6Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Renal Cell 6Prostatic Neoplasms 4Rectal Neoplasms 2Melanoma 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Breast Neoplasms 2Brain Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Fallopian Tube Mucinous Adenocarcinoma 1Ependymoma 1Astrocytoma 1Advanced Prostate Adenocarcinoma 1

Interventions

cediranib 1carboxyamido-triazole 1capmatinib 1Thalidomide 1Paclitaxel 1Gefitinib 1Fluorodeoxyglucose F18 1Fentanyl 1FPP(RGD)2 1Everolimus 1Erlotinib Hydrochloride 1Docetaxel 1CLR1404 1Bevacizumab 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × cediranib × Genitourinary × Clear all
NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡